Evidence map›Paper›PMID 25258678›Full record

ArticleRSC advances2014

3-Substituted Biquinolinium Inhibitors of AraC Family Transcriptional Activator VirF from

Prashi Jain, Jiaqin Li, Patrick Porubsky, Benjamin Neuenswander, Susan M Egan, Jeffrey Aubé, Steven Rogers

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Prashi JainCenter for Chemical Methodologies and Library Development, The University of Kansas, 2034 Becker Drive, Lawrence, Kansas, 66047, USA.
Jiaqin LiDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS, USA.
Patrick PorubskyCenter for Chemical Methodologies and Library Development, The University of Kansas, 2034 Becker Drive, Lawrence, Kansas, 66047, USA.
Benjamin NeuenswanderSpecialized Chemistry Center, The University of Kansas, 2034 Becker Drive, Lawrence, Kansas 66047, USA.
Susan M EganDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS, USA.
Jeffrey AubéCenter for Chemical Methodologies and Library Development, The University of Kansas, 2034 Becker Drive, Lawrence, Kansas, 66047, USA ; Specialized Chemistry Center, The University of Kansas, 2034 Becker Drive, Lawrence, Kansas 66047, USA ; University of Kansas Center of Biomedical Research Excellence, Center for Cancer Experimental Therapeutics, 2034 Becker Drive, Lawrence, KS, USA ; Department of Medicinal Chemistry, University of Kansas, Lawrence, KS, USA.
Steven RogersUniversity of Kansas Center of Biomedical Research Excellence, Center for Cancer Experimental Therapeutics, 2034 Becker Drive, Lawrence, KS, USA.

Funding

Phase trafficking in combinatorial chemistry: ROM polymerizationP50GM069663 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI AUBE, JEFFREY · 2003 to 2012
$18.9M
Novel Approaches for the Control of Microbial PathogensP30GM103326 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LUTKENHAUS, JOSEPH F · 2012 to 2016
$5.3M
Center for Cancer Experimental TherapeuticsP30GM103495 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI TIMMERMANN, BARBARA N · 2012 to 2014
$3.2M
NIGMS NIH HHS P30 GM103326NIGMS NIH HHS P30 GM103495NIGMS NIH HHS P50 GM069663
6 · The paper itself

Abstract

During a structure-activity relationship optimization campaign to develop an inhibitor of AraC family transcriptional activators, we discovered an unexpected transformation of a previously reported inhibitor that occurs under the assay conditions. Once placed in the assay media, the 3, 4-disubstituted dihydroquinoline core of the active analogue rapidly undergoes a decomposition reaction to a quaternary 3-substituted biquinolinium. Further examination established an SAR for this chemotype while also demonstrating its resilience to irreversible binding of biologically relevant nucleophiles.

Identifiers

PMID25258678
PMCPMC4170738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.